Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Allergan, Inc.
NASH Drug Development: Experts Argue The Case For Noninvasive Tests As Surrogate Endpoints For Approval
However, FDA officials appear skeptical that imaging-based and circulating biomarkers are ready for prime time when it comes to supporting accelerated approval of drugs for noncirrhotic nonalcoholic steatohepatitis.
Genentech is broadening its stake in the protein degradation field, following BMS and Merck & Co into molecular glue drugs.
With a pair of Phase III setbacks due to high placebo response, Relmada reports positive efficacy and safety data from an open-label trial while awaiting data from two ongoing pivotal studies for REL-1017, an NMDA antagonist.
The company blamed lack of funding for incomplete enrollment of the Phase II study in acute suicidal ideation and behavior in major depressive disorder, saying it would have reached statistical significance had it fully enrolled.
- OTC, Consumer
- Specialty Pharmaceuticals
- Controlled Release
- Site Specific
- Implantable Devices
- Surgical Equipment & Devices
- Other Names / Subsidiaries
- MAP Pharmaceuticals, Inc. (MAPP)
- Oculex Pharmaceuticals, Inc.
- SkinMedica, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.